Navigation Links
New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
Date:10/29/2008

One in five women suffer from fibroid symptoms at least 5 years before seeking treatment.

LAS VEGAS, Oct. 29 /PRNewswire/ -- At the annual meeting of the American Association of Gynecologic Laparoscopists (AAGL), ETHICON Women's Health & Urology today announced results of a seven-country study measuring the effects of uterine fibroids and associated symptoms on quality of life (QoL). Researchers found that one in five women suffer with symptomatic fibroids for more than 5 years before getting medical treatment. Further, despite diagnosis, more than one-third of women remain untreated -- either surgically or medically -- for their fibroids, which means that many women continue to experience symptoms severe enough to affect QoL.

Uterine fibroids are benign tumors made up of fibrous and muscular tissue in the uterine wall. They occur in one third of women over age thirty and are a major reason for hysterectomy worldwide. Women who have uterine fibroids may experience debilitating symptoms such as abnormal bleeding, pain, pressure in the pelvic region, painful intercourse, frequent urination or infertility.

The CHASM (Cross-Sectional Survey of HRQoL And Symptoms of Myoma) study was sponsored by ETHICON and designed to quantify the fibroid burden on a woman's QoL and to better understand current management of symptomatic fibroids. More than 2,500 adult women experiencing fibroid symptoms with a self-reported physician diagnosis or previous treatment for uterine fibroids were surveyed in the United States, Canada and five European countries. Researchers found that:

-- Overall, 22% of women who have been diagnosed with uterine fibroids

waited at least five years before getting treatment.

-- A substantial percentage of women (almost 45% of those diagnosed and

almost 70% of those with symptoms) have not sought any treatment in the

past year

-- Of those who have sought medical care and been diagnosed, more than 36%

have not received surgical or medical treatment, despite reporting

symptoms that interfere with their quality of life

-- Women who have opted for surgical treatment report a better quality of

life outcome than those who have used medication

ETHICON Women's Health & Urology currently is recruiting for two clinical trials to evaluate the safety and effectiveness of Doppler guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated bleeding (in the US) and as a treatment for the reduction of fibroid-associated symptoms (in the EU). Details about both studies can be found at: http://www.clinicaltrials.gov, keyword "doppler guided uterine artery occlusion".

Results of the CHASM study will be presented on October 30, 2008 as part of Plenary Session 7, Management of Myomas, at AAGL's annual meeting. Details about the session can be found at http://www.aagl.org/annual-meeting.

About Ethicon Women's Health and Urology

ETHICON Women's Health & Urology offers treatment solutions for a range of common, female pelvic health disorders. The technologies are marketed under the GYNECARE family of brands and include treatments for menorrhagia (heavy periods), fibroids, stress urinary incontinence and pelvic organ prolapse. ETHICON Women's Health & Urology is a division of ETHICON, Inc, a Johnson & Johnson company. For more information visit http://www.gynecare.com.


'/>"/>
SOURCE ETHICON Women?s Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):